

## Boston Medical Center

[View the current Boston Medical Center Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/2115-Boston+Medical+Center.html)

(<http://www.bioportfolio.com/bi corporate/2115-Boston+Medical+Center.html>)

### Contact Details:

**One Boston Medical Center Place**

**Boston**

**MA**

**2118**

**United States of America**

Tel:

Fax:

Email: [amy.gleason@bmc.org](mailto:amy.gleason@bmc.org)

### Recent Publications by Boston Medical Center:



- [Promoting Early Literacy in Pediatric Practice: Twenty Years of Reach Out and Read.](#)  
*Reach Out and Read (ROR) is the first pediatric, evidence-based strategy...* 18th November, 2009  
Department of Pediatrics, Boston University School of Medicine and Boston- Pediatrics. 2009 Nov 16. ([DOI Direct Link](#))
- [Boston Medical Center Pediatric Emergency Response to H1N1.](#)  
*Reach Out and Read (ROR) is the first pediatric, evidence-based strategy...* 17th November, 2009  
Boston Medical Center Pediatric Emergency Department, 21 John St, Boston,- J Emerg Nurs. 2009 Nov;35(6):580-3. Epub 2009 Aug 29. ([DOI Direct Link](#))
- [Fluorodeoxyglucose-Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer.](#)  
*SUMMARY: The hybrid technique of PET/CT has significantly impacted the...* 17th November, 2009  
Departments of Radiology and Radiation Oncology, Boston Medical Center and- AJNR Am J Neuroradiol. 2009 Nov 12. ([DOI Direct Link](#))
- [Payment reform for safety-net institutions--improving quality and outcomes.](#)  
*SUMMARY: The hybrid technique of PET/CT has significantly impacted the...* 17th November, 2009  
Department of Pediatrics, Boston Medical Center and Boston University- N Engl J Med. 2009 Nov 5;361(19):1821-3. ([DOI Direct Link](#))
- [New mTOR inhibitor for renal cell cancer.](#)  
*SUMMARY: The hybrid technique of PET/CT has significantly impacted the...* 13th November, 2009  
Boston Medical Center, Boston, Massachusetts, USA.- Oncology (Williston Park). 2009 Jul;23(8 Suppl):54-6.

- [Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.](#)  
*SUMMARY: The hybrid technique of PET/CT has significantly impacted the...*28th October, 2009  
 Boston Medical Center, Boston, Massachusetts, USA.- *Oncology (Williston Park)*. 2009 Oct;23(11 Suppl):54-6.
- [Drug essentials. An alkylating agent for CLL and NHL.](#)  
*SUMMARY: The hybrid technique of PET/CT has significantly impacted the...*28th October, 2009  
 Boston Medical Center, Boston, Massachusetts, USA.- *Oncology (Williston Park)*. 2009 Apr;23(4 Suppl):55-6.
- [Drug essentials. Small molecule multitargeted TKI therapy.](#)  
*SUMMARY: The hybrid technique of PET/CT has significantly impacted the...*28th October, 2009  
 Boston Medical Center, Boston, Massachusetts, USA.- *Oncology (Williston Park)*. 2008 Oct;22(11 Suppl):47-8.
- [Tissue Proteomics Reveals Differential and Compartment-Specific Expression of the Homologs Transgelin and Transgelin-2 in Lung Adenocarcinoma and Its Stroma.](#)  
*Discovery of tissue-specific biomarkers for human cancer is crucial for...*24th October, 2009  
 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital,- *J Proteome Res*. 2009 Nov 10. ([DOI Direct Link](#))
- [Research during pediatric residency training: outcome of a senior resident block rotation.](#)  
*BACKGROUND: The Pediatric Residency Review Committee requires programs to...*24th October, 2009  
 Boston Medical Center, Department of Pediatrics, Boston University School- *Pediatrics*. 2009 Oct;124(4):1126-34. Epub 2009 Sep 28. ([DOI Direct Link](#))
- [N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone.](#)  
*CONTEXT: Biomarkers that predict musculoskeletal response to anabolic...*20th October, 2009  
 Section of Endocrinology, Diabetes, and Nutrition, Boston University- *J Clin Endocrinol Metab*. 2009 Nov;94(11):4224-33. Epub 2009 Oct 16. ([DOI Direct Link](#))
- [Expression of Inducible Nitric Oxide Synthase in Conduits Used in Patients with Diabetes Mellitus Undergoing Coronary Revascularization.](#)  
*Abstract Background: Expression of inducible nitric oxide synthase (iNOS)...*9th October, 2009  
 Department of Cardiothoracic Surgery, Boston University School of- *J Card Surg*. 2009 Oct 7. ([DOI Direct Link](#))
- [Reversal of Paraplegia Following Repair of an Ascending Aortic Dissection.](#)  
*Abstract We report the case of a patient who presented with sudden onset...*9th October, 2009  
 Department of Cardiothoracic Surgery, The Boston Medical Center, Boston- *J Card Surg*. 2009 Oct 7. ([DOI Direct Link](#))
- [Treating diabetes and prediabetes by focusing on obesity management.](#)  
*Obesity is associated with an increased risk of developing insulin...*2nd October, 2009  
 Boston University School of Medicine, Center for Nutrition and Weight- *Curr Diab Rep*. 2009 Oct;9(5):348-54.
- [Utility of hematologic and volume, conductivity, and scatter parameters from umbilical cord blood in predicting chorioamnionitis.](#)  
*Summary We evaluated the utility of routine hematologic parameters and...*2nd October, 2009  
 Department of Pathology and Laboratory Medicine, Boston Medical Center,- *Int J Lab Hematol*. 2009 Sep 28. ([DOI Direct Link](#))

**Press Releases on Boston Medical Center:**

<a href="#">National Certification for Medical Interpreters Launched in the US</a>	24th November, 2009	International Medical Interpreters Association	WASHINGTON, Nov. 24 /PRNewswire/ -- Patients in the United States with limited English proficiency (LEP) continue to face language barriers that threaten their health and undermine their well-being.
<a href="#">Hamilton Thorne announces third quarter results</a>	24th November, 2009	Hamilton Thorne Ltd.	TSX VENTURE: HTL TORONTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorne Ltd. (TSX-V: HTL), formerly Calotto Capital Inc., a leading provider of advanced laser systems and instruments for the stem
<a href="#">Delcath Systems, Inc. Sponsors Satellite Session at World Meeting of Melanoma/Skin Cancer Centers</a>	24th November, 2009	Delcath Systems, Inc.	NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., (Nasdaq: DCTH) a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver,
<a href="#">YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA</a>	23rd November, 2009	YM BioSciences Inc.	MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
<a href="#">NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference</a>	23rd November, 2009	NuVasive, Inc.	SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine,

**BioNews Results for Boston Medical Center**



- [Jury Still Out on Whether Advanced Technology Can Improve the Outcomes of Patients With Anal Canal Cancer](#)  
 Cancernetwork.com: Nov 15 2009 1:11AM Matching: boston medical center
- [The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patien](#)  
 Genetic Engineering News: Nov 15 2009 4:07PM Matching: boston medical center

- [The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patien](#)  
*Genetic Engineering News: Nov 15 2009 2:16PM Matching: boston medical center*
- [The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patien](#)  
*Freshnews.com: Nov 15 2009 2:09PM Matching: boston medical center*
- [Pyro Pharmaceuticals Elects Robert Moellering, Jr., M.D. as Chairman of the Scientific Advisory Board](#)  
*TradingMarkets: Nov 14 2009 5:24AM Matching: boston medical center*
- [Trial Examines Whether Stem Cells Can Treat Critical Limb Ischemia](#)  
*Diagnostic & Invasive Cardiology: Nov 14 2009 2:10AM Matching: boston medical center*
- [Psoriasis treatment guidelines proposed for patients with concomitant HCV](#)  
*MedWire News: Nov 13 2009 6:24PM Matching: boston medical center*
- [Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008](#)  
*DiagnosticMicrobiology and Infectious Disease: Nov 13 2009 4:15PM Matching: boston medical center*
- [Dana-Farber Cancer Institute Selects Plateau Systems' Integrated Talent Management Suite](#)  
*Media Newswire: Nov 13 2009 6:58AM Matching: boston medical center*
- [i3 Develops H1N1 Safety Program](#)  
*eCliniqua: Nov 12 2009 6:40PM Matching: boston medical center*
- [Dainippon Sumitomo Chooses SAS](#)  
*eCliniqua: Nov 12 2009 6:40PM Matching: boston medical center*
- [Aspirin shows promise for colon cancer patients](#)  
*WTVM: Nov 12 2009 9:21AM Matching: boston medical center*
- [AMICAS PACS For Mammography at RSNA 2009 With intrinsic mammography, AMICAS PACS drives additional return on investment and increased productivity](#)  
*Yahoo! Canada: Nov 12 2009 11:26PM Matching: boston medical center*
- [Loss of HBsAg in Nucleoside-Nave HBeAg\(+\) Chronic Hepatitis B Patients Following Treatment with Entecavir or](#)  
*National AIDS Treatment Advocacy Project: Nov 11 2009 5:53PM Matching: boston medical center*
- [Entecavir and Tenofovir combination therapy in chronic Hepatitis B: Rescue therapy in patients with advanced f](#)  
*National AIDS Treatment Advocacy Project: Nov 11 2009 5:54PM Matching: boston medical center*

**Boston Medical Center Clinical Trials:**



- [A Multicenter Randomized Trial Comparing Antiglise and Lateral Plate Fixation in Ankle Fractures](#)



## Boston Medical Center Patents:

- 7517667- [Methods for promoting, inhibiting and detecting toxin entry into cells](#)
- 5763250- [Chimeric toxins](#)
- 5863891- [Chimeric toxins](#)
- 5932471- [DNA encoding chimeric toxin](#)
- 6309817- [Identification of virulence determinants activators in prokaryotic pathogens](#)
- 6379920- [Spectroscopic diagnostics for bacteria in biologic sample](#)
- 6399649- [Compositions and methods for the treatment of chronic lymphocytic leukemia](#)
- 6620583- [Diagnostic screens for type 1 diabetes \(IDDM\)](#)
- 6667038- [Prevention, diagnosis and treatment of lyme disease](#)
- 6683168- [Genes and methods that modulate apoptosis](#)
- 6917199- [Synthetic images for a magnetic resonance imaging scanner using linear combination of source images to generate contrast and spatial navigation](#)
- 7002345- [Synthetic images for a magnetic resonance imaging scanner using linear combinations of source images](#)
- 7091183- [Specific antagonists for glucose-dependent insulintropic polypeptide \(GIP\)](#)
- 5677148- [DNA encoding chimeric diphtheria toxins](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

